Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03501576 | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma | recruiting | — | 200 | Emory UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04256018 |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome |
| recruiting |
| Phase 2 |
| 30 |
| Stanford UniversityOTHER |
| 1 |
| Jul 1, 2026 |
| clinicaltrials |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | recruiting | Phase 1 | 21 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06860880 | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program | recruiting | N/A | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03829540 | CD4CAR for CD4+ Leukemia and Lymphoma | recruiting | Phase 1 | 20 | Huda SalmanOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma(EpiRev-NKT) | recruiting | Phase 1 / Phase 2 | 107 | Rong TaoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT05463263 | A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 180 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT05313243 | Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | recruiting | Phase 2 | 32 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | recruiting | Phase 3 | 218 | Dizal PharmaceuticalsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07278856 | Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06131801 | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | recruiting | — | 30 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07555431 | Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection(DOT-H) | recruiting | Phase 2 | 146 | Carlos BritesOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07001384 | A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) | recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07013565 | Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL(ACCELERATE) | recruiting | Phase 2 | 20 | New York Medical CollegeOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05976997 | Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 2 | 36 | Liling ZhangOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07220993 | Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07225985 | Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06874946 | Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | recruiting | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03932279 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma | recruiting | — | 300 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05838599 | Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides | recruiting | Early Phase 1 | 25 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07075328 | A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Otsuka Medical Devices Co., Ltd. JapanINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05680558 | Photopheresis in Early-stage Mycosis Fungoides | recruiting | Phase 2 | 74 | Columbia UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07496229 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | recruiting | Phase 1 / Phase 2 | 165 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03398161 | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | recruiting | Phase 2 | 44 | Jonathan BrammerOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05996185 | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | recruiting | Phase 2 | 22 | Yale UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies(ADAPT-HEM) | recruiting | Phase 1 / Phase 2 | 96 | Beijing BiotechINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06067347 | A Global Study of the PETAL Consortium(PETAL) | recruiting | — | 1,200 | Massachusetts General HospitalOTHER | 4 | Apr 9, 2026 | clinicaltrials |
| NCT03587844 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | recruiting | Phase 2 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05544968 | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies | recruiting | Phase 1 | 42 | Medical College of WisconsinOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04512534 | Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma(Sincerely20) | recruiting | Phase 2 | 51 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07047885 | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | recruiting | Phase 1 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07270861 | Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study | recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05376111 | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | recruiting | Phase 2 | 28 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07470996 | T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR(T-START-NR) | recruiting | — | 58 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05679895 | Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL(CARxALL) | recruiting | Phase 1 | 20 | OneChain ImmunotherapeuticsINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06316856 | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06698003 | A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 | recruiting | Phase 2 | 134 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07414758 | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy(T-START-M1) | recruiting | Phase 3 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04645199 | National Longitudinal Cohort of Hematological Diseases(NICHE) | recruiting | — | 2,300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 6, 2026source: clinicaltrials